A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...

The apparel industry accounts for 10% of greenhouse gas emissions. Biotechs are working on reengineering natural products to make more sustainable textiles, which are gaining traction.

A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...

Traditional breeding and genetic modification methods have struggled to keep pace with the rapid evolution of plant viruses. CRISPR/Cas systems, originally derived from bacterial immune responses, ...

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top ...

What are the new EPF withdrawal rules 2025 announced by EPFO? Learn 8 key changes and how they impact your EPF balance and withdrawals. These new rules aim to simplify and rationalize the earlier ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 6.54% at $68.29. The stock trailed the S&P 500, which registered a daily gain of 1.56%. On the other hand, the Dow registered a gain ...

CRISPR Therapeutics AG CRSP shares soared 8.7% in the last trading session to close at $76.78. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...